Form 4: Bristol-Myers Squibb Executive Gregory Scott Meyers Reports Changes in Beneficial Ownership
SEC Form 4
Gregory Scott Meyers, EVP, Chief Digital & Tech Officer at Bristol-Myers Squibb, reports transactions involving common stock and derivative securities, including vesting of market share units and performance shares.
Summary
- Gregory Scott Meyers, an executive at Bristol-Myers Squibb, filed a Form 4 detailing changes in his beneficial ownership of the company's stock.
- The reported transactions occurred on March 10, 2025.
- These transactions include the vesting of market share units and performance shares, as well as the withholding of shares for tax payments.
- Meyers acquired and disposed of common stock and derivative securities, resulting in adjustments to his holdings.
- The transactions involve market share units that convert into common stock based on a payout factor related to the company's stock price performance.
- Performance shares also converted into common stock based on the company's performance results.
- Following these transactions, Meyers directly owns 16,102 shares of common stock and various derivative securities, including 25,439 market share units vesting in 2028 and 38,159 performance shares vesting in 2028.
Sentiment
Score: 6
Explanation: The document is a routine filing related to executive compensation. It doesn't contain any particularly positive or negative information about the company's performance or outlook. The sentiment is neutral to slightly positive as it reflects the executive's continued stake in the company.
Positives
- The vesting of market share units and performance shares indicates that the company is meeting certain performance targets.
- The executive's continued holding of a significant number of shares suggests confidence in the company's future performance.
Future Outlook
The document outlines future vesting dates for market share units and performance shares, indicating continued equity-based compensation for the executive.
Industry Context
Executive compensation through equity-based awards is a common practice in the pharmaceutical industry to align management's interests with those of shareholders.
Comparison to Industry Standards
- Equity compensation practices vary across the pharmaceutical industry, but generally include stock options, restricted stock units, and performance-based shares.
- Companies like Johnson & Johnson (JNJ) and Pfizer (PFE) also utilize similar long-term incentive plans for their executives.
- The specific terms of these plans, such as vesting schedules and performance metrics, can differ significantly based on company-specific goals and industry benchmarks.
Stakeholder Impact
- The vesting of equity awards can impact shareholder value through potential dilution.
- Executive compensation practices are of interest to shareholders and can influence their perception of management's alignment with their interests.
Key Dates
| Date | Description |
|---|---|
| 03/10/2022 | Grant date of market share units, one-quarter of which vested on 03/10/2025. |
| 03/10/2023 | Grant date of market share units, one-quarter of which vested on 03/10/2025. |
| 03/10/2025 | Date of transactions reported, including vesting of market share units and performance shares. |
| 03/12/2025 | Date of signature on the Form 4 filing. |
| 03/10/2026 | Expiration date for some market share units. |
| 03/10/2027 | Expiration date for some market share units. |
| 03/10/2028 | Expiration date for some market share units and performance shares. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.